10
Nov
Mr . Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd Highlights:- · Total Income from operation in Q2 FY23 at ₹ 146.30 crore, up 12.5% from ₹ 130.00 crore in Q1 FY23; · During the year, company got an approval from WHO-GMP for Tablet Capsule, dry-powder Suspension products at Cephalosporin plant. · Approved dividend of ₹ 1.50/- per share for the FY21-22 at the 28th AGM held on 30th Sep, 2022. Financial Highlights (Standalone) (Amount in Cr except EPS) Particulars Q2 FY23 Q1 FY23 Y-O-Y Total Income from Operation 146.30 130.00 12.54% EBITDA 34.59 23.41 47.76% Profit before Tax 32.03 20.93…
